AllianceBernstein
BBH icon

AllianceBernstein’s VanEck Biotech ETF BBH Stock Holding History

AllianceBernstein’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-624,508
Closed -$77.8M – 3023
2017
Q4 		$77.8M Sell
624,508
-404,886
-39% -$51.7M 0.06% 375
2017
Q3 		$138M Sell
1,029,394
-3,435
-0.3% -$447K 0.1% 187
2017
Q2 		$130M Buy
1,032,829
+136,071
+15% +$16.4M 0.1% 204
2017
Q1 		$107M Buy
896,758
+241,531
+37% +$28.2M 0.09% 257
2016
Q4 		$70.5M Buy
655,227
+57,411
+10% +$6.24M 0.06% 355
2016
Q3 		$68.9M Buy
+597,816
New +$68.1M 0.06% 370

Other funds holding BBH

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
MCM
Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return
SFS
Strategic Financial Services Utica, New York $2.28B AUM 22.9% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
MJRIC
Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return
BRM
Boston Research & Management Manchester, Massachusetts $453M AUM 20.53% 1-Year Est. Return

AllianceBernstein's BBH Position: Q1 2018 in Review

AllianceBernstein sold out of VanEck Biotech ETF (BBH) in Q1 2018, closing a stake of 624,508 shares — an estimated $77.8M sold.

AllianceBernstein first reported a position in BBH in Q3 2016 and held it in 6 quarters. The position peaked at $138M in Q3 2017. 82 funds tracked by Wall St. Rank hold BBH as of Q1 2018.

  • AllianceBernstein reported no remaining VanEck Biotech ETF position as of Q1 2018 after selling out during the quarter.
  • AllianceBernstein sold 624,508 VanEck Biotech ETF shares in Q1 2018, an estimated $77.8M.
  • AllianceBernstein first reported a position in VanEck Biotech ETF in Q3 2016 and held it in 6 quarters.
  • AllianceBernstein's VanEck Biotech ETF position peaked at $138M in Q3 2017.
  • 82 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2018.

Based on AllianceBernstein's 13F filing for Q1 2018, filed 14 May 2018.